Skip to main content
SpringerLink
Log in

The clinical application of fibroblast interferon—An overview

  • Published:
Medical Oncology and Tumor Pharmacotherapy Aims and scope Submit manuscript

Abstract

Preclinical as well as clinical studies with fibroblast interferon (IFN) are still lagging behind on those with leukocyte interferon. Its side-effects seem to be less pronounced than those of human IFN-α, yet it may be slightly pyrogenic after intravenous injection. Pyrogenicity of current impure preparations might for the larger part be due to impurities.

Higher doses of HuIFN-β than of HuIFN-α are required to obtain measurable blood titers by intramuscular injections. Since there is concern about this being due to destruction of the interferon before it has reached its target organ(s), most current clinical studies use either local (e.g. intratumoral) treatment or intravenous infusions.

A study of topical treatment for acute rhinovirus infection has indicated that there is very little if any chance for fibroblast interferon to be a clinically useful substance to prevent or cure common cold. In herpetic dendritic keratitis eye drops of fibroblast interferon may be useful as such or in combination with debridement.

Topical treatment of warts (multiple intralesional injections) has been shown to yield a high success rate, especially in the case of verrucae vulgares, but less so in the case of verrucae planae juveniles. Studies on condyloma accuminatum are not so far advanced as to permit a documented conclusion.

Topical (intralesional) treatment of neoplastic diseases has been investigated, especially in Japan, to demonstrate that fibroblast interferon does have an antineoplastic effectin vivo. While there seems to be little doubt that local delivery does indeed cause tumor nodules to regress, the question is whether this procedure can offer a true clinical benefit to the patient.

Systemic (intravenous) administration for chronic hepatitis B has been investigated further: given alone or in combination with adenine-arabinoside, fibroblast interferon seems to be able to reduce the level of viral activity. Whether this will lead to a generally accepted treatment of chronic active hepatitis is difficult to say at this moment.

In treating herpes zoster in cancer patients, results have been obtained which are comparable to those found for leukocyte interferon. The practical significance of this finding must be seen in the perspective of recent developments in the chemotherapy of herpes zoster.

In breast cancer patients given intramuscular injections, metastases in the skin, but not in other organs, showed alterations suggestive of an effect on tumor progression. Yet there was no true clinical benefit for the patient. In other tumors, e.g. head and neck epithelioma, no effect was seen.

Intravenous infusions have met with some success in nasopharyngeal carcinoma: temporary stabilization or regression occurred, but no definitive cures were noted. A large neuroblastoma trial yielded negative results. Disappointing results were also obtained in non-Hodgkin's lymphoma. In initial studies on myeloma and brain tumors ‘response rates’ of 25% were recorded; the significance of this in terms of clinical benefit to the patient is not clear yet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Desmyter J, Ray M B, De Groote J, Bradburne A F, Desmet V J, Edy V G, Billau A, De Somer P, Mortelmans J: Administration of human fibroblast interferon in chronic hepatitis-B infection.Lancet ii, 645–647 (1976).

    Article  Google Scholar 

  2. Weimar W, Schellekens H, Lameijer L D F, Masurel N, Edy V G, Billiau A, De Somer P: Double-blind study of interferon administration in renal transplant recipients.Eur J clin Invest 8, 255–258 (1978).

    Article  PubMed  CAS  Google Scholar 

  3. Weimar W, Heijtink R A, Schalm S W, Van Blankenstein M, Schellekens H, Masurel N, Edy V G, Billiau A, De Somer P: Fibroblast interferon in HBsAg-positive chronic active hepatitis.Lancet ii, 1282 (1977).

    Article  Google Scholar 

  4. Billiau A, De Somer P: Clinical use of interferons in viral infections, in Stringfellow D A (ed):Interferon and Interferon Inducers Clinical Applications, pp. 113–144. New York, Marcel Dekker (1980).

    Google Scholar 

  5. Billiau A, Bloemmen J, Bogaerts M, Clays H, Van Damme J, De Ley M, De Somer P, Drochmans A, Heremans H, Kriel A, Schetz J, Tricot G, Vermylen C, Waer M: Interferon therapy in multiple myeloma failure of human fibroblast interferon administration to affect the course of light chain disease.Eur J Cancer clin Oncol 17, 875–882 (1981).

    Article  PubMed  CAS  Google Scholar 

  6. Lucero M A, Magdelenat H, Fridman W H, Pouillart P, Billardon C, Billau A, Cantell K, Falcoff E: Comparison of effects of leukocyte and fibroblast interferon in immunological parameters in cancer patients.Eur J Cancer clin Oncol 18, 243–251 (1982).

    Article  PubMed  CAS  Google Scholar 

  7. Pouillart P, Palangie T, Jouve M, Garcia-Giralt E, Fridman W H, Magdalenat H, Falcoff E, Billiau A: Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone receptors.Eur J Cancer clin Oncol 18, 929–935 (1982).

    Article  PubMed  CAS  Google Scholar 

  8. De Somer P, Edy V G, Billiau A: Interferon-induced skin reactivity in man.Lancet ii, 47–48 (1977).

    Google Scholar 

  9. Billiau A, De Somer P, Edy V G, De Clercq E, Heremans H: Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans.Antimicrob Ag Chemother 16, 59–63 (1979).

    Google Scholar 

  10. Billiau A, Edy V G, De Somer P: The clinical use of fibroblast interferon, in Chandra P (ed):Antiviral Mechanisms in the Control of Neoplasia, pp. 675–696. New York, London, Plenum Publishing Corporation (1979).

    Google Scholar 

  11. Edy V G, Billiau A, De Somer P: Non-appearance of injected fibroblast interferon in the circulation.Lancet i, 451–452 (1978).

    Article  Google Scholar 

  12. Derynck R, Remaut E, Saman E, Stanssens P, De Clercq E, Content J, Fiers W: Expression of human fibroblast interferon gene inEscherichia coli.Nature 287, 193–197 (1980).

    Article  PubMed  CAS  Google Scholar 

  13. Munk K, Kirchner H (eds):Interferon. Properties, Mode of Action Production, Clinical Application, vol. 11, Basel, S. Karger, Contributions to Oncology (1982).

    Google Scholar 

  14. Kono R, Vilcek J (eds):The Clinical Potential of Interferons. Tokyo, University of Tokyo Press (1982).

    Google Scholar 

  15. De Maeyer E, Galasso G, Schellekens H (eds):The Biology of the Interferon System. Amsterdam, Elsevier/North-Holland Biomedical Press (1981).

    Google Scholar 

  16. De Maeyer E, Galasso G, Schellekens H (eds):The Biology of the Interferon System, vol. II. Amsterdam, Elsevier/North-Holland Biomedical Press (1983).

    Google Scholar 

  17. Scott G M, Reed S, Cartwright T, Tyrrell D: Failure of human fibroblast interferon to protect against rhinovirus infection.Archs Virol 65, 135–140 (1980).

    Article  CAS  Google Scholar 

  18. Schouten T J, Weimar W, Bos J H, Bos C E, Cremers C W R J, Schellekens H: Treatment of juvenile laryngeal papillomatosis with two types of interferon.Laryngoscope 92, 686–688 (1982).

    Article  PubMed  CAS  Google Scholar 

  19. Göbel H, Arnold W, Wahn V, Treuner J, Jürgens H, Cantell K: Comparison of human fibroblast and leukocyte interferon in the treatment of severe laryngeal papillomatosis in children.Eur J Pediatr 137, 175–176 (1981).

    PubMed  Google Scholar 

  20. Heidemann E, Wilms K, Treuner J, Niethammer D: Fibroblasten-Interferon zur Behandlung des Herpes Zoster.Dt med Woschr 107, 695–697 (1982).

    CAS  Google Scholar 

  21. Merigan T C, Rand K H, Pollard R B, Abdallah P S, Jordan G W, Fried R P: Human leukocyte interferon for the treatment of herpes zoster in patients with cancer.New Engl J Med 298, 981–987 (1978).

    PubMed  CAS  Google Scholar 

  22. Müller R, Siegert W, Hofschneider H P, Deinhardt F, Frösner G, Vido I, Schmidt F W: Treatment of chronic active hepatitis B (CAHB) with human interferon-beta, in De Mayer E, Galasso G, Schellekens H (eds):The Biology of the Interferon System, pp. 355–359. Amsterdam, Elsevier/North-Holland Biomedical Press (1981).

    Google Scholar 

  23. Obert H J: Clinical trials conducted with beta-interferon in Germany, in De Maeyer E, Galasso G, Schellekens H (eds):The Biology of the Interferon System, vol. II. Amsterdam, Elsevier/North-Holland Biomedical Press (1983).

    Google Scholar 

  24. Yamazaki S: Clinical trials of interferons in Japan in viral and neoplastic diseases. in De Maeyer E, Galasso G, Schellekens H (eds):The Biology of the Interferon System, vol. II. Amsterdam, Elsevier/North-Holland Biomedical Press (1983).

    Google Scholar 

  25. Suzuki H: Effect of human fibroblast interferon (IFN-β) on HBE antigen-positive chronic active hepatitis.Antiviral Res, Spec Abstract Issue, p. 99 (1983).

  26. Suzuki H: Effects of IFN-α and-β on HBV-associated DNA polymerase positive chronic active hepatitis.Antiviral Res, Spec Abstract Issue, p. 100 (1983).

  27. Billiau A, Niethammer D, Strander H: Trials with interferon in cancer patients in Europe, in String-fellow D (ed):Clinical Application of Interferons and Their Inducers. New York, Marcel Dekker (in press).

  28. Seto W H, Choo Y C, Hsu C, Merigan T C, Tan Y H, Ma H K, Ng M H: Local treatment of intra-epithelial neoplasia of cervix with IFN-α and IFN-β, in De Maeyer E, Galasso G, Schellekens H (eds):The Biology of the Interferon System, vol. II. Amsterdam, Elsevier/North-Holland Biomedical Press (1983).

    Google Scholar 

  29. Berthold F, Treuner J, Niethammer D, Lampert F: Neuroblastomstudie NBL79 der Gesellschaft für Pädiatrische Onkologie. Zwischenbereicht nach 1 Jahr.Klin Pädiat 193, 198–201 (1981).

    CAS  Google Scholar 

  30. Berthold F, Treuner J, Brandeis W E, Evers G, Haas R J, Harms D, Jürgens H, Kaatsch P, Michaelis J, Lampert F: Neuroblastomstudie NBL79 der Gesellschaft für Pädiatrische Onkologie. Zwischenbereicht nach 2 Jahren.Kline Pädiat 194, 262–269 (1982).

    Article  CAS  Google Scholar 

  31. Treuner J, Niethammer D, Dannecker G, Hagmann R, neef V, Hofschneider P H: Successful treatment of nasopharyngeal carcinoma with interferon.Lancet i, 817–818 (1980).

    Article  Google Scholar 

  32. Treuner J, Niethammer D, Dannecker G, Jobke A, Aldenhoff P, Kremens B, Nessler G, Bömer H: Treatment of nasopharyngeal carcinoma in children with fibroblast interferon, in Grundmann E (ed):Cancer Campaign, vol. 5, p. 309. Stuttgart, Gustav Fischer. (1981).

    Google Scholar 

  33. Siegert W, Theml H, Fink U, Emmerich B, Kaudewitz P, Huhn D, Nöning L, Abb J, Joester K E, Bartl R, Riethmüller G, Wilmanns W: Treatment of non-Hodgkin's lymphoma of low-grade malignancy with human fibroblast interferon.Anti-Cancer Res 2, 193–198 (1982).

    CAS  Google Scholar 

  34. Misset J L, Mathé G, Gastiaburu J, Goutner A, Dorval T I, Gouveia J, Hayat M, Jasmin C, Schwarzenberg L, Machover D, Ribaud P, de Vassal F, Horoszewicz J S: Traitement des leucémies et des lymphomes par les interférons. III. Essai de traitement des localisations méningées de la leucémie aiguë et des lymphomes non hodgkiniens par l'interféron beta administré par voie intrathécale.Biomedicine 36, 167–170 (1982).

    CAS  Google Scholar 

  35. Misset J L, Mathé G, Gastiaburu J, Goutner A, Dorval T, Gouveia J, Hayat M, Jasmin C, Schwarzenberg L, Machover D, Ribaud P, de Vassal F, Horoszewicz J S: Treatment of lymphoid neoplasias with interferon. I. Human fibroblastic beta-interferon in malignant gammapathies. Phase II trial.Anti-Cancer Res 2, 63–66 (1982).

    CAS  Google Scholar 

  36. Horoszewicz J S, Leong S S, Ito M, Buffett R F, Karakousis C, Holyoke E, Job L, Dölen J G, Carter W A: Human fibroblast interferon in human neoplasia: clinical and laboratory study.Cancer Treat Rep 62, 1899–1906 (1978).

    PubMed  CAS  Google Scholar 

  37. Nagai M, Arai T, Kohno S, Kohase M: Interferon therapy on malignant brain tumors, in Kono R, Vilcek J (eds):The Clinical Potential of Interferons, pp. 257–273. Tokyo, University of Tokyo Press (1982).

    Google Scholar 

  38. Jacobs L, O'Malley J, Freeman A, Ekes R: Intrathecal interferon reduces exacerbations of multiple sclerosis.Science 214, 1026–1028 (1981).

    Article  PubMed  CAS  Google Scholar 

  39. Billiau A: Interferon therapy: pharmacokinetic and pharmacological aspects.Archs Virol 67, 121–133 (1981).

    Article  CAS  Google Scholar 

  40. Guttermann J U, Fine S, Quesada J, Horning S J, Levine J F, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z: Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.Ann intern Med 96, 549–556 (1982).

    Google Scholar 

  41. Billiau A, Heine J W, Van Damme J, Heremans H, De Somer P: Tolerability of pure fibroblast interferon in man.Ann N Y Acad Sci 350, 374–375 (1980).

    Article  PubMed  CAS  Google Scholar 

  42. Edy V G, Billiau A, De Somer P: Comparison of rate of clearance of human fibroblast and leukocyte interferon from the circulatory system of rabbits.J Infect Dis 133, A18-A21 (1976).

    PubMed  Google Scholar 

  43. Billiau A, Van Damme J, Van Leuven F, Edy V G, De Ley M, Cassiman J J, Van den Berghe H, De Somer P: Human fibroblast interferon for clinical trials: production, partial purification, and characterization.Antimicrob Ag Chemother 16, 49–55 (1979).

    CAS  Google Scholar 

  44. Billiau A, Heremans H, Ververken H, Van Damme J, Carton H, De Somer P: Tissue distribution of human interferons after exogenous administration in rabbits, monkeys and mice.Archs Virol 68, 19–25 (1981).

    Article  CAS  Google Scholar 

  45. Vilcek J, Sulea I T, Zerebeckyj I L, Yip Y K: Pharmacokinetic properties of human fibroblast and leukocyte interferon in rabbits.J clin Microbiol 11, 102–105 (1980).

    PubMed  CAS  Google Scholar 

  46. Hanley D F, Wiranowska-Stewart M, Stewart II W E: Pharmacology of interferons. I. Pharmacologic distinctions between human leukocyte and fibroblast interferons.Int J Immunopharmac 1, 219–226 (1979).

    Article  CAS  Google Scholar 

  47. Morser J, Kabayo J P, Hutchinson D W: Differences in sialic acid content of human interferons.J gen Virol 41, 175–178 (1978).

    Article  PubMed  CAS  Google Scholar 

  48. Heine J W, Van Damme J, De Ley M, Billiau A, De Somer P: Purification of human fibroblast interferon by zinc chelate chromatography.J gen Virol 54, 47–56 (1981)

    Article  PubMed  CAS  Google Scholar 

  49. Heine J, Billiau A, Van Damme J, De Somer P: Human fibroblast interferon: subpopulation with different pharmacokinetics behavior, in Kono R, Vilcek J (eds):The Clinical Potential of Interferons, pp. 69–74. Tokyo, University of Tokyo Press (1982).

    Google Scholar 

  50. Olsen R L: Personal communication at the 100th Anniversary Meeting of the American Dermatological Association (Williamsburg, VA).Loc. citati: Dermatology News 9 (6), 1 & 6 (1983).

    Google Scholar 

  51. De Clercq E: Selective anti-herpes drugs, in de La Maza LM (ed):Proceedings of the International Symposium on Medical Virology. Amsterdam, Elsevier/North-Holland (in press).

Download references

Author information

Authors and Affiliations

  1. Rega Institute, University of Leuven, Minderbroedersstraat 10, B-3000, Leuven, Belgium

    A. Billiau

Authors
  1. A. Billiau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Billiau, A. The clinical application of fibroblast interferon—An overview. Med. Oncol. & Tumor Pharmacother. 1, 87–96 (1984). https://doi.org/10.1007/BF02934979

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02934979

Key words

Search

Navigation